Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder
Phase of Trial: Phase I/II
Latest Information Update: 27 Oct 2015
At a glance
- Drugs Vigabatrin (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Proof of concept; Therapeutic Use
- 27 Oct 2015 Results will be presented at the 62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry 2015, according to Catalyst Pharmaceuticals, Inc. media release.
- 22 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jun 2015 Top-line results published in the Media Release.